Strategic Investment Momentum Life Sciences has secured a strategic growth investment from Parthenon Capital in 2026, signaling a signal of credible expansion and potential for scaled partnerships, channels, and larger projects with biopharma clients.

Large-Scale Engagement The company executes over one million patient and healthcare provider engagements via a nationwide network of 800+ nurse educators, indicating a mature delivery model that can scale engagements for new pharma clients and real-world data initiatives.

Awarded Credibility Consistent recognition as a Great Place to Work for multiple years and industry accolades (ELITE 100, Patient Support Awards) enhance credibility for enterprise customers seeking stable, employee-driven programs and strong patient support capabilities.

Leadership Focus Led by President and CEO Andrea Heslin Smiley with a seasoned executive team, the company presents a stable leadership narrative that can reassure large biopharma partners during contract negotiations and long-term programs.

Productive Partnerships Expertise in patient engagement with the One Voice model and real-world data integration positions Momentum as a favorable partner for biopharma teams seeking optimized intervention mixes and data-driven patient support strategies.